About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 712949, 8 pages
http://dx.doi.org/10.1155/2013/712949
Review Article

Cardioprotective Effects of ω-3 PUFAs in Chronic Kidney Disease

1Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-Ro, Jongno-Gu, Seoul 110-744, Republic of Korea
2Department of Internal Medicine, Dong-A University, 3Ga-1 Dongdaesin-Dong, Seo-Gu, Busan 602-715, Republic of Korea

Received 29 January 2013; Accepted 7 March 2013

Academic Editor: Gabriella Calviello

Copyright © 2013 Su Mi Lee and Won Suk An. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. N. Foley, P. S. Parfrey, and M. J. Sarnak, “Clinical epidemiology of cardiovascular disease in chronic renal disease,” American Journal of Kidney Diseases, vol. 32, no. 5, supplement 3, pp. S112–S119, 1998. View at Scopus
  2. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” The New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1305, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Stenvinkel, O. Heimbürger, B. Lindholm, G. A. Kaysen, and J. Bergström, “Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome),” Nephrology Dialysis Transplantation, vol. 15, no. 7, pp. 953–960, 2000. View at Scopus
  4. M. J. Sarnak, A. S. Levey, A. C. Schoolwerth et al., “Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention,” Hypertension, vol. 42, no. 5, pp. 1050–1065, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. E. L. Schiffrin, M. L. Lipman, and J. F. E. Mann, “Chronic kidney disease: effects on the cardiovascular system,” Circulation, vol. 116, no. 1, pp. 85–97, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. C. R. Harper and T. A. Jacobson, “Managing dyslipidemia in chronic kidney disease,” Journal of the American College of Cardiology, vol. 51, no. 25, pp. 2375–2384, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Mizobuchi, D. Towler, and E. Slatopolsky, “Vascular calcification: the killer of patients with chronic kidney disease,” Journal of the American Society of Nephrology, vol. 20, no. 7, pp. 1453–1464, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Marchioli, “Dietary supplementation with N-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial,” The Lancet, vol. 354, no. 9177, pp. 447–455, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Dyerberg, H. O. Bang, and N. Hjorne, “Fatty acid composition of the plasma lipids in Greenland Eskimos,” American Journal of Clinical Nutrition, vol. 28, no. 9, pp. 958–966, 1975. View at Scopus
  10. F. B. Hu, L. Bronner, W. C. Willett et al., “Fish and omega-3 fatty acid intake and risk of coronary heart disease in women,” Journal of the American Medical Association, vol. 287, no. 14, pp. 1815–1821, 2002. View at Scopus
  11. W. S. An, S. E. Kim, K. H. Kim et al., “Comparison of fatty acid contents of erythrocyte membrane in hemodialysis and peritoneal dialysis patients,” Journal of Renal Nutrition, vol. 19, no. 4, pp. 267–274, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. G. D. Eslick, P. R. C. Howe, C. Smith, R. Priest, and A. Bensoussan, “Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis,” International Journal of Cardiology, vol. 136, no. 1, pp. 4–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Tomiyama, K. Takazawa, S. I. Osa et al., “Do eicosapentaenoic acid supplements attenuate age-related increases in arterial stiffness in patients with dyslipidemia?: a preliminary study,” Hypertension Research, vol. 28, no. 8, pp. 651–655, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. W. L. Hall, K. A. Sanders, T. A. B. Sanders, and P. J. Chowienczyk, “A high-fat meal enriched with eicosapentaenoic acid reduces postprandial arterial stiffness measured by digital volume pulse analysis in healthy men,” Journal of Nutrition, vol. 138, no. 2, pp. 287–291, 2008. View at Scopus
  15. S. Kanai, K. Uto, K. Honda, N. Hagiwara, and H. Oda, “Eicosapentaenoic acid reduces warfarin-induced arterial calcification in rats,” Atherosclerosis, vol. 215, no. 1, pp. 43–51, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. J. X. Kang and A. Leaf, “Evidence that free polyunsaturated fatty acids modify Na+ channels by directly binding to the channel proteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 8, pp. 3542–3546, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Leaf, “The electrophysiologic basis for the antiarrhythmic and anticonvulsant effects of n-3 polyunsaturated fatty acids: heart and brain,” Lipids, vol. 36, supplement, pp. S107–S110, 2001. View at Scopus
  18. G. C. Shearer, J. V. Pottala, J. A. Spertus, and W. S. Harris, “Red blood cell fatty acid patterns and acute coronary syndrome,” PLoS ONE, vol. 4, no. 5, Article ID e5444, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Hussein, E. Ah-Sing, P. Wilkinson, C. Leach, B. A. Griffin, and D. J. Millward, “Long-chain conversion of [13C]linoleic acid and α-linolenic acid in response to marked changes in their dietary intake in men,” Journal of Lipid Research, vol. 46, no. 2, pp. 269–280, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Friedman and S. Moe, “Review of the effects of omega-3 supplementation in dialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 1, no. 2, pp. 182–192, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Grimsgaard, K. H. Bønaa, J. B. Hansen, and E. S. P. Myhre, “Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans,” American Journal of Clinical Nutrition, vol. 68, no. 1, pp. 52–59, 1998. View at Scopus
  22. W. S. Harris and C. Von Schacky, “The Omega-3 Index: a new risk factor for death from coronary heart disease?” Preventive Medicine, vol. 39, no. 1, pp. 212–220, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. W. S. Harris, S. A. Sands, S. L. Windsor, et al., “Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation,” Circulation, vol. 110, no. 12, pp. 1645–1649, 2004.
  24. O. D. Rangel-Huerta, C. M. Aguilera, M. D. Mesa, and A. Gil, “Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomakers: a systematic review of randomised clinical trials,” British Journal of Nutrition, vol. 107, supplement 2, pp. S159–S170, 2012.
  25. J. J. Ågren, S. Väisänen, O. Hänninen, A. D. Muller, and G. Hornstra, “Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 57, no. 4-5, pp. 419–421, 1997. View at Scopus
  26. S. L. Archer, D. Green, M. Chamberlain, A. R. Dyer, and K. Liu, “Association of dietary fish and n-3 fatty acid intake with hemostatic factors in the coronary artery risk development in young adults (CARDIA)study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 7, pp. 1119–1123, 1998. View at Scopus
  27. G. A. Kaysen, “The microinflammatory state in uremia: causes and potential consequences,” Journal of the American Society of Nephrology, vol. 12, no. 7, pp. 1549–1557, 2001. View at Scopus
  28. P. Muntner, L. L. Hamm, J. W. Kusek, J. Chen, P. K. Whelton, and J. He, “The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease,” Annals of Internal Medicine, vol. 140, no. 1, pp. 9–17, 2004. View at Scopus
  29. T. Pischon, S. E. Hankinson, G. S. Hotamisligil, N. Rifai, W. C. Willett, and E. B. Rimm, “Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women,” Circulation, vol. 108, no. 2, pp. 155–160, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. G. B. Perunicic-Pekovic, Z. R. Rasic, S. I. Pljesa et al., “Effect of n-3 fatty acids on nutritional status and inflammatory markers in haemodialysis patients,” Nephrology, vol. 12, no. 4, pp. 331–336, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. K. S. Hassan, S. K. Hassan, E. G. Hijazi, and K. O. Khazim, “Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients,” Renal Failure, vol. 32, no. 9, pp. 1031–1035, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. W. S. An, H. J. Kim, K. H. Cho, and N. D. Vaziri, “Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney,” American Journal of Physiology, vol. 297, no. 4, pp. F895–F903, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. C. N. Serhan, N. Chiang, and T. E. Van Dyke, “Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators,” Nature Reviews Immunology, vol. 8, no. 5, pp. 349–361, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. M. James, S. Proudman, and L. Cleland, “Fish oil and rheumatoid arthritis: past, present and future,” Proceedings of the Nutrition Society, vol. 69, no. 3, pp. 316–323, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Deike, R. G. Bowden, J. J. Moreillon, et al., “The effects of fish oil supplementation on markers of inflammation in chronic kidney disease patients,” Journal of Renal Nutrition, vol. 22, no. 6, pp. 572–577, 2012.
  36. J. H. O'Keefe Jr., H. Abuissa, A. Sastre, D. M. Steinhaus, and W. S. Harris, “Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions,” American Journal of Cardiology, vol. 97, no. 8, pp. 1127–1130, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Mozaffarian, R. J. Prineas, P. K. Stein, and D. S. Siscovick, “Dietary fish and n-3 fatty acid intake and cardiac electrocardiographic parameters in humans,” Journal of the American College of Cardiology, vol. 48, no. 3, pp. 478–484, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. J. X. Kang, “Reduction of heart rate by omega-3 fatty acids and the potential underlying mechanisms,” Frontiers in Cardiac Electrophysiology, vol. 3, article 416, 2012.
  39. P. M. Kris-Etherton, W. S. Harris, and L. J. Appel, “Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease,” Circulation, vol. 106, no. 21, pp. 2747–2757, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. T. Zhao, Q. Chen, Y. X. Sun et al., “Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials,” Annals of Medicine, vol. 41, no. 4, pp. 301–310, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. M. B. Katan, P. L. Zock, and R. P. Mensink, “Dietary oils, serum lipoproteins, and coronary heart disease,” American Journal of Clinical Nutrition, vol. 61, no. 6, supplement, pp. S1368–S1373, 1995. View at Scopus
  42. S. M. Grundy, D. M. Hegsted, A. Astrup, J. O. Hill, W. H. M. Saris, and G. Taubes, “Dietary fat: at the heart of the matter,” Science, vol. 293, no. 5531, pp. 801–804, 2001. View at Scopus
  43. W. S. An, S. M. Lee, Y. K. Son, et al., “Effect of omega-3 fatty acids on the modification of erythrocyte membrane fatty acid content including oleic acid in peritoneal dialysis patients,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 86, no. 1-2, pp. 29–34, 2012.
  44. W. S. An, S. M. Lee, Y. K. Son, et al., “Omega-3 fatty acid supplementation increases 1, 25-dihydroxyvitamin D and fetuin-A levels in dialysis patients,” Nutrition Research, vol. 32, no. 7, pp. 495–502, 2012.
  45. N. D. Riediger, R. A. Othman, M. Suh, and M. H. Moghadasian, “A systemic review of the roles of n-3 fatty acids in health and disease,” Journal of the American Dietetic Association, vol. 109, no. 4, pp. 668–679, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. B. M. Egan, G. Lu, and E. L. Greene, “Vascular effects of non-esterified fatty acids: implications for the cardiovascular risk factor cluster,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 60, no. 5-6, pp. 411–420, 1999. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Lu, E. L. Greene, T. Nagai, and B. M. Egan, “Reactive oxygen species are critical in the oleic acid-mediated mitogenic signaling pathway in vascular smooth muscle cells,” Hypertension, vol. 32, no. 6, pp. 1003–1010, 1998. View at Scopus
  48. R. C. Block, W. S. Harris, K. J. Reid, and J. A. Spertus, “Omega-6 and trans fatty acids in blood cell membranes: a risk factor for acute coronary syndromes?” American Heart Journal, vol. 156, no. 6, pp. 1117–1123, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. F. Paganelli, J. M. Maixent, M. J. Duran, R. Parhizgar, G. Pieroni, and S. Sennoune, “Altered erythrocyte n-3 fatty acids in Mediterranean patients with coronary artery disease,” International Journal of Cardiology, vol. 78, no. 1, pp. 27–32, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. K. Son, S. M. Lee, S. E. Kim, et al., “Association between vascular calcification scores on plain radiographs and fatty acid contents of erythrocyte membrane in hemodialysis patients,” Journal of Renal Nutrition, vol. 22, no. 1, pp. 58–66, 2012.
  51. M. Ando, T. Sanaka, and H. Nihei, “Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients,” Journal of the American Society of Nephrology, vol. 10, no. 10, pp. 2177–2184, 1999. View at Scopus
  52. H. Sampath and J. M. Ntambi, “Polyunsaturated fatty acid regulation of genes of lipid metabolism,” Annual Review of Nutrition, vol. 25, pp. 317–340, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. W. S. Harris and D. Bulchandani, “Why do omega-3 fatty acids lower serum triglycerides?” Current Opinion in Lipidology, vol. 17, no. 4, pp. 387–393, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. P. M. Kearney, L. Blackwell, R. Collins, et al., “Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis,” The Lancet, vol. 371, no. 9607, pp. 117–125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. D. E. Weiner and M. J. Sarnak, “Managing dyslipidemia in chronic kidney disease,” Journal of General Internal Medicine, vol. 19, no. 10, pp. 1045–1052, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. M. F. Holick, “Medical progress: vitamin D deficiency,” The New England Journal of Medicine, vol. 357, no. 3, pp. 266–281, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. C. F. Garland, E. D. Gorham, S. B. Mohr, and F. C. Garland, “Vitamin D for cancer prevention: global perspective,” Annals of Epidemiology, vol. 19, no. 7, pp. 468–483, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Mezawa, T. Sugiura, M. Watanabe et al., “Serum vitamin D levels and survival of patients with colorectal cancer: post-hoc analysis of a prospective cohort study,” BMC Cancer, vol. 10, article 347, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. L. G. Danescu, S. Levy, and J. Levy, “Vitamin D and diabetes mellitus,” Endocrine, vol. 35, no. 1, pp. 11–17, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Kayaniyil, R. Vieth, R. Retnakaran et al., “Association of vitamin D with insulin resistance and β-cell dysfunction in subjects at risk for type 2 diabetes,” Diabetes Care, vol. 33, no. 6, pp. 1379–1381, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Theuer, E. Shagdarsuren, D. N. Muller et al., “Inducible NOS inhibition, eicosapentaenoic acid supplementation, and angiotensin II-induced renal damage,” Kidney International, vol. 67, no. 1, pp. 248–258, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. W. F. C. Rigby, S. Denome, and M. W. Fanger, “Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA,” The Journal of Clinical Investigation, vol. 79, no. 6, pp. 1659–1664, 1987. View at Scopus
  63. Y. C. Li, G. Qiao, M. Uskokovic, W. Xiang, W. Zheng, and J. Kong, “Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure,” Journal of Steroid Biochemistry and Molecular Biology, vol. 89-90, pp. 387–392, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. C. Li, J. Kong, M. Wei, Z. F. Chen, S. Q. Liu, and L. P. Cao, “1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system,” The Journal of Clinical Investigation, vol. 110, no. 2, pp. 229–238, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. T. J. Wang, M. J. Pencina, S. L. Booth et al., “Vitamin D deficiency and risk of cardiovascular disease,” Circulation, vol. 117, no. 4, pp. 503–511, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. M. L. Melamed, E. D. Michos, W. Post, and B. Astor, “25-hydroxyvitamin D levels and the risk of mortality in the general population,” Archives of Internal Medicine, vol. 168, no. 15, pp. 1629–1637, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. M. L. Melamed, B. Astor, E. D. Michos, T. H. Hostetter, N. R. Powe, and P. Muntner, “25-Hydroxyvitamin D levels, race, and the progression of kidney disease,” Journal of the American Society of Nephrology, vol. 20, no. 12, pp. 2631–2639, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. D. Santoro, L. Gitto, A. Ferraro, E. Satta, V. Savica, and G. Bellinghieri, “Vitamin D status and mortality risk in patients with chronic kidney disease,” Renal Failure, vol. 33, no. 2, pp. 184–191, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. D. Zehnder, R. Bland, E. A. Walker et al., “Expression of 25-hydroxyvitamin D3-1α-hydroxylase in the human kidney,” Journal of the American Society of Nephrology, vol. 10, no. 12, pp. 2465–2473, 1999. View at Scopus
  70. J. N. Artaza, R. Mehrotra, and K. C. Norris, “Vitamin D and the cardiovascular system,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 9, pp. 1515–1522, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. P. J. Shobeiri N, M. A. Adams, and R. M. Holden, “Cardiovascular disease in an adenine-induced model of chronic kidney disease: the temporal link between vascular calcification and haemodynamic consequences,” Journal of Hypertension, vol. 31, no. 1, pp. 160–168, 2013.
  72. H. Nishizawa, K. Hamazaki, T. Hamazaki, S. Fujioka, and S. Sawazaki, “The relationship between tissue RBC n-3 fatty acids and pulse wave velocity,” In Vivo, vol. 20, no. 2, pp. 307–310, 2006. View at Scopus
  73. M. Szweras, D. Liu, E. A. Partridge et al., “α2-HS glycoprotein/fetuin, a transforming growth factor β/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling,” The Journal of Biological Chemistry, vol. 277, no. 22, pp. 19991–19997, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. M. L. Burr, A. M. Fehily, J. F. Gilbert et al., “Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART),” The Lancet, vol. 2, no. 8666, pp. 757–761, 1989. View at Scopus
  75. D. Kromhout, E. J. Giltay, and J. M. Geleijnse, “N-3 fatty acids and cardiovascular events after myocardial infarction,” The New England Journal of Medicine, vol. 363, no. 21, pp. 2015–2026, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. E. C. Rizos, E. E. Ntzani, E. Bika, M. S. Kostapanos, and M. S. Elisaf, “Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis,” Journal of the American Medical Association, vol. 308, no. 10, pp. 1024–1033, 2012.
  77. J. H. Christensen, J. Aarøe, N. Knudsen et al., “Heart rate variability and n-3 fatty acids in patients with chronic renal failure—a pilot study,” Clinical Nephrology, vol. 49, no. 2, pp. 102–106, 1998. View at Scopus
  78. T. A. Mori, V. Burke, I. B. Puddey et al., “The effects of ω3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial,” Journal of Hypertension, vol. 27, no. 9, pp. 1863–1872, 2009. View at Publisher · View at Google Scholar · View at Scopus